TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03819686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living ACTS website
Description: Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching \~20-minutes of videos from the website)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard transplant education procedures
Description: Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two \~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard transplant education procedures
Description: Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two \~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
Study: NCT00545558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
Study: NCT03646799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: reference drug
Study: NCT02139722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Doctor, PA + PPN
Description: The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
Study: NCT01000168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill therapy and conventional walking therapy.
Description: The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill therapy and conventional walking therapy.
Description: The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period.
Study: NCT00361374

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid
Description: 1 gram/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: 1 gram/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 980 milligram/day
Study: NCT03274869

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02858050

Intervention type: DEVICE
Intervention: Portal-724 MEMs Cap
Study: NCT03107364

Intervention type: OTHER
Intervention: Hospital stay
Description: Collection of hospital lengths of stay and readmissions

Intervention type: OTHER
Intervention: Hospital stay
Description: Collection of hospital lengths of stay and readmissions
Study: NCT04205331

Intervention type: DEVICE
Intervention: Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
Description: Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
Study: NCT01070212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft gum
Description: . Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: firm gum
Description: . Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no gum
Description: . Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
Study: NCT05454644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Centred Prescription Model
Description: Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~* Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~* Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~* Correct and practical directions: Medication Regimen Complexity Index (MRCI).~* Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~* Drug-disease interactions: Beers Criteria.~* Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan
Study: NCT00497289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT/LCT 20 %
Description: daily i.v. infusion for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipidem 20%
Description: daily i.v. infusion for up to 5 days
Study: NCT04453280

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of anti-SARS-CoV-2-antibodies
Description: Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of anti-SARS-CoV-2-antibodies
Description: Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
Study: NCT03999437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERBINAFINE HYDROCHLORIDE (1%)
Description: Topical liquid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BUTENAFINE HYDROCHLORIDE (1%)
Description: Topical liquid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Topical liquid solution
Study: NCT03144856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg, po, qd, every 4 weeks.
Study: NCT02405507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat bread with wheat germ

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat bread without wheat germ
Study: NCT03795103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulator
Description: A 12-week program of neuromuscular electrical stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Walking sessions
Description: A 12-week program of walking sessions performed outdoors and independently

Intervention type: OTHER
Group type: OTHER
Intervention: Advices
Description: The usual practice associated with an information leaflet outlining tips for active living and walking.
Study: NCT02541656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.
Description: The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
Study: NCT01055249

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen, Hydrocortisone
Description: Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Study: NCT03697421

Intervention type: OTHER
Intervention: Relationship Education
Description: We will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.).

Intervention type: OTHER
Intervention: Employment Services
Description: For couples in need of job search, job retention, and career advancement services, we will provide employment services.
Study: NCT04185558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraft
Description: Whole Blood Clot (WBC) gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
Study: NCT02203240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03581981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Brief version of Prolonged Exposure (PE) provided in 30 minute sessions in primary care (PC)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)-Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
Study: NCT00373399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Marijuana (0% THC)
Description: Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low THC marijuana (1.8 %THC)
Description: Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC marijuana (3.9% THC)
Description: Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
Study: NCT01549431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
Study: NCT00962195

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: purple sweet potato (PSP)-juice
Description: Daily oral intake of 3x 125 ml of PSP-juice or control juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: purple sweet potato (PSP)-juice
Description: Daily oral intake of 3x 125 ml of PSP-juice or control juice
Study: NCT04523987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
Study: NCT02324218

Intervention type: OTHER
Intervention: Data collection
Description: Data extraction from CPRD database of UK.

Intervention type: OTHER
Intervention: Data collection
Description: Data extraction from CPRD database of UK.
Study: NCT01469533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal mechanical manipulation intervention
Description: Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (\<5 ms) force-time impulse with a peak force magnitude of approximately 176N.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation intervention
Description: Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
Study: NCT04731454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet (CD)
Description: All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Nordic Diet (ND)
Description: All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
Study: NCT02178748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Single dose of 1x10\^8pfu MVA85A intramuscular vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Single dose of 1x10\^8pfu MVA85A intramuscular vaccination
Study: NCT03633968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary sinus lift
Description: maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary sinus lift
Description: maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
Study: NCT02744222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-054 180 mcg
Description: 180 mcg intramuscularly once every two weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: 30 mcg intramuscularly once a week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-054 240 mcg
Description: 240 mcg intramuscularly once every two weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscularly once a week (0,5 ml)
Study: NCT02795273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grass-SPIRE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00446810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benfotiamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01615328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervios ChronOs
Description: The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonion
Description: The ACDF surgery will be carried out with Bonion after randomization procedure.
Study: NCT03548298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARAT
Description: After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
Study: NCT00082173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400mg daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg daily for 8 weeks
Study: NCT00746590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolarix (tretazicar co-administered with caricotamide)
Description: Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
Study: NCT04453280

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 diagnostic rapid test
Description: The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
Study: NCT02976441

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study: NCT02606903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 autoinjector
Study: NCT03527225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
Study: NCT05283967

Intervention type: DIAGNOSTIC_TEST
Intervention: urine colorimetric assay
Description: Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.

Intervention type: DIAGNOSTIC_TEST
Intervention: urine colorimetric assay
Description: Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.